DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02042664

CompletedPhase 3

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

44

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥30•HbA1c 7-10%

Primary endpoint

•Intracardiac triglyceride

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02042664
Org study ID2010 -022792-57
Secondary ID2010-14AP HM

Timeline

Milestones

Study first posted2014-01-23estimated
Last update posted2026-05-07actual
Study start2011-01 (month precision)
Primary completion2015-01actual (month precision)
Study completion2015-06actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•- Patients with type 2 diabetes according to WHO criteria
•Age> 18 years
•BMI ≥ 30 kg/m2
•HbA1c> 7% and <10%
•Processing by ADO (Metformin and Glimepiride)
•Effective contraception (for women)
•Signed informed consent by the patient before inclusion in the protocol

Exclusion criteria

•Ongoing pregnancy or become pregnant within six months of the study protocol
•Breastfeeding
•Recent weight loss (> 5% of total weight)
•Treatments changing the distribution of adipose tissue as corticosteroids or glitazones
•Acute coronary syndrome or unstable angina during the last three months
•Contraindications to cardiac MRI (mechanical heart valve, pacemaker, metallic intraocular foreign body, claustrophobia)
•Contraindication to cold test: Raynaud's syndrome
•Contraindication to exenatide:
–Neoplasia active or untreated or in remission for less than 5 years (except for basal cell carcinoma or in situ cervical or prostate)
–Contraindication to ADO (depending on specific product) in combination with exenatide.
–History of kidney transplant or dialysis or plasmatique creatinine> 1.5 mg / dL for men and> 1.2 mg / dL for women
–Digestive diseases, including gastroparesis
–plasma triglycerides> 1000 mg / dL
–History of pancreatitis confirmed biologically
–contraindication or hypersensitivity to Exenatide or one of its social coverage composantsAbsence

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint/low confidence

intracardiac triglyceride

Time frame:3 years

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.